The Living Wage Foundation and ShareAction have designed this toolkit to help investors in UK markets understand how and why to encourage their portfolio companies to adopt the real Living Wage. The toolkit covers what the real Living Wage is,…
The Access to Medicine Index ranks 20 of the world’s largest research-based pharmaceutical companies on the basis of how they manage risks and opportunities related to access to medicine in low- and middle-income countries. The collaborative engagement is a long-term engagement project for tracking the progress of pharmaceutical companies towa
The Access to Medicine Index measures a range of value drivers within the pharmaceutical business model, including governance, R&D, pricing and compliance. The collaborative engagement covers the 19 listed companies in the 2018 Access to Medicine Index. These companies together account for approximately 60-70% of global pharmaceutical revenues.
Expanding access to medicine will help pharma companies enhance shareholder value in several ways:
- Unlock growth potential in emerging markets by reaching new populations.
- Mitigate the risk of unethical conduct.
- Enhance corporate reputations.
- Contribute to the creation of healthy societies.
Companies covered in the collaborative engagement: AbbVie Inc., Astellas Pharma Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Co., Daiichi-Sankyo Co. Ltd., Eisai Co. Ltd., Eli Lilly & Co., Gilead Sciences Inc., GlaxoSmithKline plc, Johnson & Johnson, Merck KGaA, Merck & Co., Novartis AG, Novo Nordisk A/S, Pfizer Inc., Roche Holding AG, Sanofi, Takeda Pharmaceutical Co. Ltd.